Myostatin & activin inhibition

One of 6 mechanistic pathways to 💪 Build muscle & strength · 8 options

Myostatin is the brake. Animals and the handful of humans with loss-of-function mutations are extraordinarily muscular, which makes this the most mechanistically compelling target in the whole field — and the one where delivery has repeatedly defeated good biology.

🩸 Is this pathway actually your problem?

No commercial myostatin assay exists, so there is nothing here that measures the mechanism directly. What you can do is watch for collateral damage — liver enzymes on anything oral, hematocrit on anything androgenic.

Comprehensive Metabolic Panel (CMP)Complete Blood Count (CBC) with DifferentialIGF-1 (Insulin-like Growth Factor 1)

⚗️ Enhanced Athlete — On-Cycle Monitoring covers these in one panel →

What engages this pathway

Ordered by how directly each one acts on the mechanism above — never by how much trial evidence exists. Each links to its full breakdown with dosing, half-life and vendor.

💉 Follistatin 344

Binds myostatin and activin A directly. The gene-therapy versions produce dramatic hypertrophy in primates. Injected peptide has a short half-life and poor tissue targeting, so the gap between mechanism and result is delivery, not biology.

🧪 Theoretical / mechanistic

💉 Follistatin (FLGR242)

Follistatin binds and neutralizes myostatin directly, which is the most upstream version of this pathway's argument. FLGR242 is marketed as the fragment that skips activin binding — the liability that derailed Bimagrumab's class. Plausible engineering, and no human data to say whether the selectivity survives in a body.

🧪 Theoretical / mechanistic

💉 ACE-083

A follistatin-Fc fusion injected into a specific muscle. It produced real, measurable local hypertrophy in human trials — and did not improve function, which is why development stopped. Growth without strength is a genuinely instructive result.

✅ Clinically validated

💉 Bimagrumab

Blocks the activin type-II receptor, so myostatin and activin can't signal at all. Human trials show simultaneous muscle gain and fat loss. The most convincing human data for this pathway by a distance.

✅ Clinically validated

💉 YK-11

Increases follistatin in myoblast culture, which is the basis for the myostatin-inhibition claim. Kept in the Vault on Cam's decision despite the SARM-adjacent classification; it is hepatotoxic in practice and bloodwork is not optional.

🧪 Theoretical / mechanistic⚠ Safety flag

🧬 Epicatechin

A cocoa flavanol that reduces myostatin and raises follistatin in small human studies. The effect size is nothing like the pharmacological agents — but it is oral, safe and the direction is right.

🧪 Theoretical / mechanistic

🧬 Turkesterone

An ecdysteroid claimed to work through a non-androgenic anabolic route. The rodent data is often cited and rarely replicated in humans; product purity is a real problem across the category.

🧪 Theoretical / mechanistic

🧬 Ecdysterone

The better-characterized ecdysteroid, with one small human trial showing hypertrophy. Estrogen-receptor-β binding is the proposed mechanism. Interesting, unreplicated.

🧪 Theoretical / mechanistic
Nothing here is ranked by evidence tier. A lot of what works in this space has never had the trial run, and sorting by trial count would bury exactly the compounds you came looking for. The tier is a label. The mechanism is the map.

What actually decides this outcome, in order of size

The congenital phenotype everybody quotes was produced by an absence of signaling from conception. Ranked by how much of the outcome each one owns:

  1. Developmental timing, which is the difference between the phenotype and the drug. Myostatin regulation and its relationship to muscle growth was characterized with follistatin as the natural antagonist Lee 2001. Loss-of-function animals and people were built without the brake, through the whole of muscle development. A drug given to a 40-year-old removes the brake for a few months on a system that has already finished building, and there is no reason to expect the same result.
  2. What the human programs actually delivered, which is a consistent and surprising answer. Bimagrumab increased lean mass and reduced body fat mass in adults with type 2 diabetes Heymsfield 2021, and it has since been trialed alongside semaglutide for obesity Heymsfield 2026. In sporadic inclusion body myositis it did not deliver the functional benefit its mechanism predicted Amato 2021. The class has repeatedly moved body composition and repeatedly failed to move function.
  3. Delivery and the off-target problem, which stopped an entire program. ACE-031, a soluble activin receptor, was studied in ambulatory boys with Duchenne muscular dystrophy Campbell 2017. The activin receptor family is not confined to muscle, and that is the mechanistic reason a systemic ligand trap produces effects nobody wanted.
  4. The retreat to local administration, which worked and then did not translate. ACE-083 increased muscle volume locally in healthy volunteers Glasser 2018 and as a follistatin-based ligand trap produced localized hypertrophy in models Pearsall 2019. In a randomized phase 2 in Charcot-Marie-Tooth disease, the muscle volume did not become function Thomas 2022. Bigger is not stronger, and this class has demonstrated that more clearly than any other.
  5. The compounds available to a reader, last, and none of them is any of the above. The clinical antimyostatin story has been reviewed as a case of great expectations meeting results Nielsen 2021 Rodgers 2022, and the items on this page that can actually be bought are a research peptide, an unlicensed androgen and two plant sterols.

The order to run these in, and what has to be true first

Understand which molecule you are actually being offered, take the arm with human safety data seriously, and treat the rest as an experiment with a liver panel attached.

  1. Do the resistance training first, because it is the only intervention here with a hypertrophy result in healthy adults. Nothing in this class has been shown to add strength to a trained person Nielsen 2021, and the trials that moved lean mass did so in disease or in metabolic populations Heymsfield 2021.
  2. Baseline panel before anything, and this page needs it more than most. Comprehensive Metabolic Panel (CMP) for transaminases and bilirubin, Complete Blood Count (CBC) with Differential, Lipid Panel (Cholesterol, HDL, LDL, Triglycerides), Total Testosterone with SHBG (Sex Hormone-Binding Globulin) and IGF-1 (Insulin-like Growth Factor 1). Selective androgen receptor modulators have a documented hepatotoxicity literature Mohamed 2023, which makes a baseline liver panel a condition of proceeding rather than a suggestion.
  3. Bimagrumab is the item with real human data and it is a clinical antibody. Its results are in metabolic and neuromuscular populations Heymsfield 2021 Amato 2021 Heymsfield 2026, not in healthy lifters, and it is not something a reader obtains responsibly.
  4. ACE-083 is the local-administration idea and its phase 2 answer is published. Volume increased Glasser 2018; function did not follow Thomas 2022. That pair of results is the most useful thing on this page for anybody deciding what to expect from hypertrophy without loading.
  5. Follistatin 344 and Follistatin (FLGR242) are a gene therapy literature being sold as an injectable peptide. Follistatin gene therapy has been trialed in sporadic inclusion body myositis Mendell 2017, and transgenic follistatin expression increases muscle mass in pigs Chang 2017. Neither is a vial of peptide, and recombinant follistatin has a short circulating half-life and binds heparan sulfate avidly, which is the pharmacokinetic reason the systemic version was never straightforward.
  6. YK-11 is an unlicensed androgen receptor modulator with a myostatin story attached. It regulates myogenic differentiation through a follistatin-dependent route in cell work Kanno 2013, and the class it belongs to has published liver injury case series Mohamed 2023 and adverse event reports Leciejewska 2023. It is the item here most likely to cause harm to a reader.
  7. Epicatechin is the best-behaved item on the page and its effect is small. It changed molecular modulators of skeletal muscle growth Gutierrez-Salmean 2014 and improved strength with a follistatin signal in older adults Mafi 2019. It also inhibited aerobic adaptations to cycling training in one study Schwarz 2018, which is a trade an endurance athlete should know about.
  8. Turkesterone and Ecdysterone are phytoecdysteroids and are not myostatin inhibitors at all. 20-hydroxyecdysone's route from plant extract toward clinical use has been reviewed Dinan 2021. They are on this page because of a shared marketing category rather than a shared mechanism.

What gets bought for this that cannot move it

The category that fails structurally is the systemic ligand trap. Myostatin, activin A and several bone morphogenetic proteins share receptors, so a molecule that sequesters enough of one to matter reaches the others. That is the mechanistic reason the ACE-031 program in Duchenne muscular dystrophy ran into off-target effects Campbell 2017, and it is why the field moved to local administration Glasser 2018 and to more selective antibodies Rodgers 2022.

The most important negative on this page is that volume did not become function. A randomized phase 2 of a local ligand trap increased muscle size without the functional gain Thomas 2022, and bimagrumab did not deliver in inclusion body myositis either Amato 2021. Muscle grown without the loading that normally accompanies growth is not the same tissue, and this class is the cleanest demonstration of that fact in human pharmacology.

Here is the extrapolation, labeled as one. The one endpoint this class has moved reliably in humans is the FAT compartment alongside lean mass Heymsfield 2021 Heymsfield 2026. IF that is where the real pharmacology lives, THEN the honest future of activin pathway blockade is as a partner to incretin therapy for preserving lean mass during weight loss rather than as a hypertrophy agent — which is what the combination trial was designed to test. That is a prediction about where the field is going, not evidence that a reader should take anything.

And what is buyable here is not what was studied. The trials used clinical antibodies and gene therapy Mendell 2017 Amato 2021; the shelf offers a research peptide, an unlicensed androgen with hepatotoxicity reports Mohamed 2023, and two plant sterols Dinan 2021. If the goal is more muscle, Substrate, cell volume & training capacity and Androgen & anabolic-receptor signaling have better evidence, and Satellite cells & local repair covers the repair side.

How you would know it was working, on a real read-out and a real timescale

This page makes a prediction with a hard falsifier. If a myostatin intervention is doing what it is sold to do, lean mass and limb circumference should rise AND a strength measure should rise with them. If size rises and strength does not, the reader has reproduced Thomas 2022 at their own expense, and there is nothing further to wait for.

  • A fixed strength measure and a fixed limb circumference, monthly. Both, always together. This pairing is the entire read-out of the page, because the published failure mode is the two diverging Glasser 2018 Thomas 2022.
  • Comprehensive Metabolic Panel (CMP) at baseline, 6 weeks and 12 weeks on anything oral and unlicensed. The androgen modulator class has published liver injury case series Mohamed 2023 and adverse event data Leciejewska 2023, and transaminases rise before jaundice does. Six weeks because that is inside the window in which the reported injuries presented.
  • Total Testosterone with SHBG (Sex Hormone-Binding Globulin) and LH & FSH before and at 12 weeks on YK-11. Androgen receptor modulators suppress the axis, and the suppression is the cost that outlasts the cycle. Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) on the same draws, because that class lowers high-density lipoprotein cholesterol measurably.
  • IGF-1 (Insulin-like Growth Factor 1) once, and understand what it is not. It is not a myostatin read-out. It exists here as a nutrition and growth-axis reference value so that a change in lean mass can be interpreted against something.
  • 12 weeks before a verdict, and the number has a reason. Measurable change in lean mass in the human trials of this class accumulated over months of dosing Heymsfield 2021, so a four-week assessment is measuring water, glycogen and enthusiasm.

What will fool you. Limb circumference rises with glycogen, with sodium and with a week of higher training volume, none of which is hypertrophy. Starting any of these coincides with training harder, and the training explains the strength. A follistatin result obtained by gene transfer Mendell 2017 or by transgenic expression Chang 2017 says nothing about an injected peptide with a short half-life. Epicatechin may blunt endurance adaptation while helping strength Schwarz 2018, so an athlete measuring only one of them will get half the answer. And a vial bought without an assay contains whatever it contains.

Sources read for these sections

The other 5 routes to build muscle & strength

Pick the pathway that matches where you are actually stuck. An appetite drug does nothing for someone who already undereats.

GH / IGF-1 axis16 optionsAndrogen & anabolic-receptor signaling15 optionsSatellite cells & local repair11 optionsSubstrate, cell volume & training capacity20 optionsRecovery, sleep & the anabolic window between sessions8 options

You know the goal. Skool has the plan.

This pathway is one arm of The Build muscle & strength Blueprint. The members' version has where this arm sits in the sequence, what to stack it with, and the markers that tell you to keep going or stop.

Open The Build muscle & strength Blueprint in Skool →

$10/mo, cancel anytime.

← Open this pathway in the interactive Vault

Frequently asked questions

What is the myostatin & activin inhibition pathway for build muscle & strength?

Myostatin is the brake. Animals and the handful of humans with loss-of-function mutations are extraordinarily muscular, which makes this the most mechanistically compelling target in the whole field — and the one where delivery has repeatedly defeated good biology.

What compounds and supplements work through myostatin & activin inhibition?

8 options are mapped to this pathway in the Vault, including Follistatin 344, Follistatin (FLGR242), ACE-083, Bimagrumab. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 2 carry clinical validation and 6 are mechanistic predictions.

How do I know if myostatin & activin inhibition is actually my problem?

No commercial myostatin assay exists, so there is nothing here that measures the mechanism directly. What you can do is watch for collateral damage — liver enzymes on anything oral, hematocrit on anything androgenic. The markers worth checking are Comprehensive Metabolic Panel (CMP), Complete Blood Count (CBC) with Differential, IGF-1 (Insulin-like Growth Factor 1).

Are the 6 theoretical options for myostatin & activin inhibition worth considering?

Unproven is not the same as ineffective. Of the 8 options on this pathway, 2 have clinical validation and 6 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.

Where this goes next

Test itEnhanced Athlete — On-Cycle MonitoringThe panel that says whether this is your problemGo deeperThe Muscle & Strength BlueprintThe free week-by-week structure behind this goal
The full protocol$10/mo

Everything above is the free case for Myostatin & activin inhibition. The protocol — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.

The Muscle & Strength Blueprint
Educational and research reference only — not medical advice, and not a recommendation for human use. Mechanistic predictions are exactly that: what the biology suggests should happen, which is not the same as what has been shown to happen.

↑ Back to on this page

The blueprint this pathway sits insideThe Muscle & Strength Blueprint →The full 20-week stack this pathway belongs to — every arm, the sequence, and the bloodwork.